Published in Transplantation on January 15, 2011
Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol (2015) 0.89
Characterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fetal systemic inflammatory response. Am J Reprod Immunol (2013) 0.83
Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clin Exp Immunol (2012) 0.82
Differential effects of activated human renal epithelial cells on T-cell migration. PLoS One (2013) 0.80
Mechanisms and mediators of inflammation: potential models for skin rejection and targeted therapy in vascularized composite allotransplantation. Clin Dev Immunol (2012) 0.80
Identification of biomarkers to assess organ quality and predict posttransplantation outcomes. Transplantation (2012) 0.80
Effector mechanisms of rejection. Cold Spring Harb Perspect Med (2013) 0.79
Peripherally circulating CD4⁺ FOXP3⁺ CXCR3⁺ T regulatory cells correlate with renal allograft function. Scand J Immunol (2012) 0.78
Mechanisms by which heme oxygenase rescue renal dysfunction in obesity. Redox Biol (2014) 0.75
In vitro immunological effects of blocking CCR5 on T cells. Inflammation (2015) 0.75
Biomarkers in Transplantation-Proteomics and Metabolomics. Ther Drug Monit (2016) 0.75
Differential gene expression pattern in biopsies with renal allograft pyelonephritis and allograft rejection. Clin Transplant (2016) 0.75
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature (2006) 5.19
Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med (2003) 4.35
Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17
RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet (1994) 3.64
Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev (2000) 3.18
The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol (2002) 2.94
Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant (2004) 2.35
Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol (2001) 1.63
Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation (2006) 1.60
Ischemia-reperfusion and immediate T cell responses. Cell Immunol (2007) 1.55
Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A (1997) 1.48
Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis (2001) 1.42
The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol (1998) 1.41
Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol (2001) 1.40
Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol (2001) 1.29
Is the proximal tubular cell a proinflammatory cell? Nephrol Dial Transplant (2000) 1.27
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Chemokine receptors in inflammation: an overview. J Immunol Methods (2003) 1.15
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation (2002) 1.14
Chemokine receptor-dependent alloresponses. Immunol Rev (2003) 1.12
CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation (2004) 1.11
Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation (2003) 1.04
Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood (2002) 0.96
High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant (2004) 0.95
Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function. Transplantation (1999) 0.93
Molecular analyses of human renal allografts: differential intragraft gene expression during rejection. Kidney Int Suppl (1997) 0.91
Renal allograft rejection: beta-chemokine involvement in the development of tubulitis. Transplantation (2000) 0.91
A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol Immunol (2009) 0.89
Post-transplant renal tubulitis: the recruitment, differentiation and persistence of intra-epithelial T cells. Am J Transplant (2003) 0.89
Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum Immunol (1995) 0.87
Call for revolution: a new approach to describing allograft deterioration. Am J Transplant (2002) 0.87
Chemokines: coded messages for T-cell missions. Front Biosci (2008) 0.85
Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol (2004) 0.85
Immune profiling: molecular monitoring in renal transplantation. Front Biosci (2003) 0.82
The role of chemokines in acute renal allograft rejection and chronic allograft injury. Front Biosci (Landmark Ed) (2009) 0.81
Expression of the chemokine receptor CCR1 in human renal allografts. Nephrol Dial Transplant (2007) 0.78
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
Care of the potential organ donor. N Engl J Med (2004) 2.66
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation (2014) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain (2009) 1.91
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med (2009) 1.76
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int (2006) 1.68
APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation (2016) 1.68
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog (2006) 1.66
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology (2005) 1.63
Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation (2006) 1.61
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61
The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol (2012) 1.60
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation (2011) 1.51
Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy. Kidney Int (2012) 1.50
Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant (2002) 1.48
Kidney and pancreas transplantation. Am J Transplant (2003) 1.45
Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis (2004) 1.45
Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology (2006) 1.44
Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant (2004) 1.42
LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest (2010) 1.41
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation (2005) 1.40
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol (2010) 1.38
Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity? J Clin Endocrinol Metab (2004) 1.38
BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. Am J Physiol Renal Physiol (2006) 1.36
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Assessment of acute renal transplant rejection with blood oxygen level-dependent MR imaging: initial experience. Radiology (2005) 1.27
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res (2006) 1.26
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol (2009) 1.23
Hepatic abscess in patients with chronic granulomatous disease. Ann Surg (2002) 1.22
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 1.19
Pancreatic precursors and differentiated islet cell types from murine embryonic stem cells: an in vitro model to study islet differentiation. Diabetes (2003) 1.19
Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant (2002) 1.19
Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery (2004) 1.18
Liver biopsy findings in chronic hepatitis B. Hepatology (2009) 1.18
Vascular access outcomes and medication use: a USRDS study. Semin Dial (2006) 1.15
Donation after cardiac death: the University of Wisconsin experience. Ann Transplant (2004) 1.14